Skip to content

Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial

The Efficacy of Testosterone Replacement in Treating Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00260390
Enrollment
Unknown
Registered
2005-12-01
Start date
2004-09-30
Completion date
Unknown
Last updated
2006-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysthymic Disorder

Keywords

Dysthymic Disorder, HPG hypofunctioning, Testosterone replacement

Brief summary

Growing evidence supports the notion that Late-onset Dysthymic disorder in middle aged men may be associated with age-related HPG hypofunctioning. In this study we seek to examine the efficacy of Testosterone replacement for this condition. Hypothesis: Testosterone replacement will be more effective than placebo, in treating men with late onset Dysthymic Disorder and hypo-gonadism.

Interventions

DRUGTestoviron

Sponsors

National Alliance for Research on Schizophrenia and Depression
CollaboratorOTHER
Sheba Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
MALE
Age
40 Years to 80 Years

Inclusion criteria

1. Male, age 40-80 years. 2. Diagnosed with hypogonadism (total T level below 350 ng/dl), but not previously treated. 3. Diagnosis of Dysthymic disorder with onset after age 40. 4. PSA \< 4.0. 5. Normal digital exam of the prostate in the preceding 1 year. 6. For subjects currently taking an antidepressant: Current antidepressant treatment last 6 weeks or longer, with decent dose and with no remission (or with partial remission only HAM-D \> 12). 7. Able to give informed consent.

Exclusion criteria

1. Acute, severe, or unstable prostatitis, symptomatic prostatic hypertrophy, polycythemia, severe acne, breast cancer, prostate cancer, or hypopituitarism. 2. Currently being treated with testosterone. 3. Meets lifetime criteria for schizophrenia, schizoaffective disorder, any bipolar disorder (i.e., BP-I, BP-II, or BP NOS); or a major depressive episode in the preceding 5 years. 4. Current suicidal risk. 5. Current (past year) substance abuse or dependence.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale (HAM-d)
Clinical Global Impression- Change (CGI-C)
Profile of Mood States (POMS)
Beck Depression Inventory (BDI)
Sheehan Disability Scale
Self Anchoring Scale (SAS)
Affective Balance Scale (ABS)
International Index of Erectile Function (IIEF)
Aging Male Symptom rating (AMS)
Clinical Global Impression (CGI)

Countries

Israel

Contacts

Primary ContactGuy Orr, MD
orrg@netvision.net.il972-52-6666577

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026